Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration (Dry AMD)

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2014 by Ocata Therapeutics
Sponsor:
Information provided by (Responsible Party):
Ocata Therapeutics
ClinicalTrials.gov Identifier:
NCT01344993
First received: April 28, 2011
Last updated: November 3, 2014
Last verified: April 2014